# Safety & Efficacy Study of EGF Cancer Vaccine to Treat Stage IV Biomarker Positive, Wild Type EGF-R NSCLC Patients

> **NCT02187367** · PHASE3 · TERMINATED · sponsor: **Bioven Europe** · enrollment: 106 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **BIOLOGICAL:** EGF Vaccine

## Key facts

- **NCT ID:** NCT02187367
- **Lead sponsor:** Bioven Europe
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-05
- **Primary completion:** 2019-05-01
- **Final completion:** 2019-09-06
- **Target enrollment:** 106 (ACTUAL)
- **Why stopped:** Sponsor decision based on slow recruitment and new emerging drug combinations
- **Last updated:** 2019-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02187367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02187367, "Safety & Efficacy Study of EGF Cancer Vaccine to Treat Stage IV Biomarker Positive, Wild Type EGF-R NSCLC Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02187367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*